Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
Aurobindo Pharma shares rose 1.80% after USFDA cleared its generic Tofacitinib tablets for immediate US launch, targeting a $494 million market and adding to 586 ANDA approvals.
Paras Healthcare has refiled its DRHP with SEBI for a ₹1,800 crore IPO, combining a ₹500 crore fresh issue and a ₹1,300 crore offer for sale by promoter and investors.
RBI cut FY27 GDP growth to 6.6% from 6.9% and held the repo rate at 5.25%, citing West Asia risks, higher energy prices and supply disruptions.
India’s IPO pipeline for 2026 remains large despite a geopolitical-driven slowdown, with SEBI extending approval validity and founders facing sharper investor scrutiny on profitability and cash flows.
India is weighing a sale of up to 2% in Hindustan Zinc for about ₹5,000 crore, as Vedanta separately launches an OFS to sell 1.59%.
Alembic Pharmaceuticals has secured USFDA final approval for Haloperidol tablets across five strengths, taking its cumulative ANDA approvals to 240, including 221 final and 19 tentative.
RBI kept the repo rate at 5.25% and rolled out bond, swap and deposit measures, including wider FAR access and FCNR(B) hedging support till September 30, 2026.
Hindustan Zinc shares extended a six-session slide after a report said the government is weighing a 2% stake sale that could raise up to ₹5,000 crore.
Bharat Forge touched fresh highs as North America Class 8 net orders surged to 47,200 units, while India CV demand, defence opportunities and a premium FY27 valuation stayed in focus.
RBI kept repo at 5.25% and announced FAR expansion, relaxed NRI-OCI limits, concessional forex swaps and FCNR(B) support till Sep 30 to ease dollar liquidity.
The RBI kept the repo rate at 5.25% and retained a neutral stance, while warning that West Asia-driven oil shocks and rupee weakness could lift inflation and slow growth.
Alembic Pharmaceuticals has reported multiple USFDA final approvals across tablets and injectables, adding new US-facing generics and expanding its cumulative ANDA approval base.
RBI kept the repo rate at 5.25% on June 5, 2026, while cutting FY27 growth to 6.6% and raising its CPI inflation projection to 5.1%.
Hindustan Zinc extended a six-session decline after a report said the government may sell up to 2% stake, reviving supply concerns for the stock.
India’s Income Tax Amendment Ordinance, 2026 makes interest income and capital gains on government securities tax-free for FIIs, retrospectively from April 1, 2026.
Indian benchmarks stayed volatile after the RBI kept the repo rate at 5.25% with a neutral stance, as Nifty moved between 23,331 and 23,516.